Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022
May 27 2022 - 7:45AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announces that management will be attending
the Jefferies Healthcare Conference at the Marriott Marquis in New
York City. Autolus’ Chief Executive Officer Dr. Christian Itin will
participate in a Fireside Chat on Thursday, June 9 at 9.00 – 9.30
am ET (2:00 pm – 2.30 pm BST) and the Company will also be
attending one-on-one investor meetings at the event.
An audio webcast of the Fireside Chat will be on
the Events section of the Autolus website. An archived version will
also be available through the Company’s website for a limited time
following the conference.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the Company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
Contact:
Olivia Manser+44 (0) 7780
471568o.manser@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-917-513-5303susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Sep 2023 to Sep 2024